Clinical Trial Update: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib in combination with capecitabine in advanced or metastatic HER2-negative breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-07-12